"We are proud to partner with Dr. Czarnota, Dr. Yaffe, and their team at Sunnybrook as they conduct ground-breaking research into breast cancer treatment monitoring," said Sebastien Gignac, ART's President and CEO. "The SoftScan imaging system's ability to provide highly-sensitive functional information on the evolution of cancer lesions allows ART to contribute to the development of personalized medicine and help maximize the efficacy of therapies for women with breast cancer", concluded Mr. Gignac.
About the SoftScan® system
The SoftScan ® optical breast imaging system has been designed first as a complementary diagnostic tool to mammography, with ultimate uses in the detection and treatment monitoring of breast cancer. Its non-invasive, painless approach uses time-domain optical imaging technology, which may allow clinicians to better locate and characterize breast tumors as benign or malignant and could provide faster assessment of therapeutic effectiveness. Unlike mammography whose use must be strictly limited, the SoftScan system emits no radiation and can be safely used as often as needed to monitor patients. The device was created and developed by ART Advanced Research Technologies Inc., and has obtained regulatory approvals for its commercialization in Canada and in Europe.